
    
      There is the potential to identify: 1) an association between CSF P-tau and in vivo
      18F-MK6240 uptake; 2) a mechanism by which tau pathology may contribute to orexin
      dysfunction; 3) evidence that orexin dysfunction disrupts sleep and CBT rhythm; and, 4) CNS
      orexin dysfunction as a new therapeutic target for AD prevention.
    
  